Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

GEMCITABIN EBEWE 1000MG-100ML VAIL - SFDA Drug Approval Details

Approvals/SFDA/GEMCITABIN EBEWE 1000MG-100ML VAIL

Authorized

GENERIC

GEMCITABIN EBEWE 1000MG-100ML VAIL

Unknown🇸🇦 Saudi Food and Drug Authority

Approval Date: N/A
Approval ID: e29b896f815b18b8
Company: Unknown
Type: Generic

Approval Details

Approval Id: e29b896f815b18b8
Drug Approval Sfda Name: GEMCITABIN EBEWE 1000MG-100ML VAIL
Trade Name: GEMCITABIN EBEWE 1000MG-100ML VAIL
Generic Name: GEMCITABINE
Register Number: 50-355-11
Register Year: 2011
Drug Type: Generic
Route Of Administration: Intravenous use
Package Type: Vial
Package Size: 1
Size: 100
Size Unit: ml
Legal Status: Prescription
Authorization Status: Valid
Marketing Status: Marketed
Product Control: Uncontrolled
Storage Conditions: store below 25°c
Shelf Life: 24 Months
Distribution Site: Hospital
Description Code: 7000000572-1000-100000073871
Price: 321.95

Active Ingredients

Authorized

Quick Info

Agency

SFDA

Country

🇸🇦

Approval ID

e29b896f815b18b8

Type

Generic

Back to SFDA Approvals